BUY Conviction3/5 Analysis quality60/100 breakthrough results from clinical trials
The YouTuber suggests Inovio Pharmaceuticals as a short squeeze play, highlighting its pipeline of 11 potential drugs, many in Phase 2 or later stages. Despite being heavily shorted (23% of float), he believes a single breakthrough product could send shares higher, squeezing out short sellers, especially with over a third of shares owned by institutions.
“of course all it takes is one good product and a breakthrough result to send the shares higher and then squeeze those shorts out.”